Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (490)	3/8/1999 4:29:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 4974

Anyone have any nominations? Here's a decent candidate..... Pharmacia & Upjohn and Centocor Sign Co-Promotion Agreement for Fragmin(R) in Unstable Angina BRIDGEWATER, N.J. and MALVERN, Pa., March 8 /PRNewswire/ -- Pharmacia & Upjohn (NYSE: PNU) and Centocor, Inc. (Nasdaq: CNTO) today announced an agreement to co-promote Pharmacia & Upjohn's FRAGMIN(R) (dalteparin sodium injection) in the United States. Under the agreement, Centocor will promote FRAGMIN to cardiovascular specialists across the U.S. after marketing clearance by the U.S. Food and Drug Administration of a new indication for the treatment of unstable angina. FRAGMIN is currently under FDA review for this indication. FRAGMIN, a low molecular weight heparin preparation, is marketed by Pharmacia & Upjohn in more than 40 countries. In the U.S., it is currently marketed by Pharmacia & Upjohn for the prevention of deep-vein thrombosis in patients at risk undergoing abdominal surgery. (snip)